KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Emergent BioSolutions (EBS) Capital Expenditures (2016 - 2026)

Emergent BioSolutions has reported Capital Expenditures over the past 17 years, most recently at $2.4 million for Q1 2026.

For Q1 2026, Capital Expenditures rose 60.0% year-over-year to $2.4 million; the TTM value through Mar 2026 reached $2.5 million, up 133.78%, while the annual FY2025 figure was $1.6 million, 15.79% down from the prior year.
Capital Expenditures for Q1 2026 was $2.4 million at Emergent BioSolutions, up from -$8.3 million in the prior quarter.
Over five years, Capital Expenditures peaked at $51.0 million in Q2 2022 and troughed at -$82.8 million in Q4 2022.
A 5-year average of $3.9 million and a median of $2.4 million in 2026 define the central range for Capital Expenditures.
Biggest five-year swings in Capital Expenditures: soared 4700.0% in 2024 and later plummeted 2866.67% in 2025.
Year by year, Capital Expenditures stood at -$82.8 million in 2022, then surged by 151.21% to $42.4 million in 2023, then tumbled by 99.29% to $300000.0 in 2024, then plummeted by 2866.67% to -$8.3 million in 2025, then skyrocketed by 128.92% to $2.4 million in 2026.
Business Quant data shows Capital Expenditures for EBS at $2.4 million in Q1 2026, -$8.3 million in Q4 2025, and $7.7 million in Q3 2025.